Table 1

Logistic regression analysis on pre-treatment factors and sustained combined response*

Pre-treatment factor†	Comparison	Odds ratio‡(95% CI)	p Value
Multivariate analyses of all treatment arms (n = 518). LAM, lamivudine; PEG-IFNα-2a, peginterferon α-2a; v, versus.
*Combined ALT normalisation and an HBV DNA level of <20 000 copies/ml after 48 weeks of treatment and 24 weeks of treatment-free follow-up; †ALT at screening was included in the model but was not a significant predictor of response (p = 0.952); ‡each odds ratio adjusted for other variables in the model.
Age	10 year decrease	1.26 (1.0 to 1.5)	0.018
Gender	Female v male	1.93 (1.1 to 3.4)	0.022
Body weight	10 kg increase	1.10 (0.9 to 1.3)	0.273
Baseline ALT	1 log₁₀ unit (IU/l)	3.69 (1.7 to 8.1)	0.001
	increase
HBV DNA	1 log₁₀ unit	1.28 (1.1 to 1.4)	<0.001
	(copies/ml) decrease
HBV genotype			<0.001
	A v B	0.42 (0.1 to 1.2)	0.097
	A v C	0.33 (0.1 to 0.9)	0.030
	A v D	0.97 (0.3 to 2.7)	0.958
	B v C	0.79 (0.5 to 1.3)	0.344
	B v D	2.31 (1.3 to 4.2)	0.006
	C v D	2.9 (1.7 to 5.0)	<0.001
Treatment	PEG-IFNα-2a v LAM	1.84 (1.1 to 3.0)	0.014
	PEG-IFNα-2a+LAM	2.19 (1.3 to 3.6)	0.002
	v LAM
	PEG-IFNα-2a v	1.19 (0.8 to 1.9)	0.460
	PEG-IFNα-2a+LAM
Treatment by	–	–	0.018
HBV genotype
interaction